Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer Mar 27, 2025 | Ovarian Cancer
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors Aug 5, 2024 | Non-Hodgkin Lymphoma
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Aug 5, 2024 | Non-Hodgkin Lymphoma
CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation Feb 29, 2024 | Uncategorized
